(Press-News.org) Based on results from the CheckMate743 trial, the dual regimen of ipilimumab and nivolumab is the standard of care for the treatment of unresectable pleural mesothelioma. But research published today in the Journal of Thoracic Oncology (JTO) showed that a group of Australian patients treated with that immunotherapy combination experienced higher levels of toxicity than were reported in the clinical trial results. The study is available here: https://www.jto.org/article/S1556-0864(23)02370-5/fulltext.
JTO is the official journal of the International Association for the Study of Lung Cancer.
Australia has one of the highest rates of asbestos-associated diseases, and mesothelioma remains an area of unmet need with a five-year overall survival (OS) rate of 10%.
First-line immunotherapy with ipilimumab and nivolumab is now a standard of care for resectable pleural mesothelioma following the CheckMate743 (CM743) trial, with supportive data from the later-line single-arm MAPS2 trial. RIOMeso examines survival and toxicity of this regimen in real-world practice.
Dr. Ned McNamee of The Kinghorn Cancer Centre & St. Vincent's Hospital, Darlinghurst, Australia and fellow researchers retrospectively collected demographic and clinicopathological data from 119 Australian patients across 11 medical centers who underwent treatment with ipilimumab and nivolumab in both first-line and subsequent settings for pleural mesothelioma. Survival outcomes were assessed using the Kaplan-Meier method, and toxicity was evaluated through the CTCAE v5.0.
The median age was 72, 83% were male, 92% were ECOG ≤1, 50% were past or current smokers and 78% had known asbestos exposure. 50% were epithelioid, 19% sarcomatoid, 14% biphasic and 17% unavailable. Ipilimumab and nivolumab were used in first-line therapy in 75% of patients.
• Median overall survival (mOS) for the entire cohort was 14.5 months.
• First-line use of ipilimumab and nivolumab was observed in 75% of patients.
• Patients treated in the second or later-line had a mOS of 15.4 months.
• No statistically significant difference in mOS was found between epithelioid and non-epithelioid histology.
• Approximately 24% of patients experienced CTCAE grade ≥ 3 adverse events, with colitis being the most frequent.
The RIOMeso study marks a significant milestone as the first detailed report of real-world survival and toxicity outcomes in Australian patients undergoing ipilimumab and nivolumab treatment for pleural mesothelioma., according to Dr. McNamee. The findings suggest that, in real-world practice, combination immunotherapy may have poorer survival outcomes and appears more toxic compared with clinical trial data, emphasizing the importance of understanding the treatment landscape beyond controlled trial settings.
However, Dr. McNamee urged caution in interpreting these results.
“There is certainly survival benefit of the Checkmate743 regimen over chemotherapy, especially in the non-epithelioid group; however, perhaps there is more equipoise in epithelioid patients. Careful patient selection may mitigate some of the risk of toxicity, but our study demonstrates that the non-chemotherapy option is not necessarily less toxic,” he said.
About IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the JTO
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.
END
Australian patients coping with mesothelioma experienced higher levels of toxicity on CheckMate743 regimen than reported in clinical trials
2023-11-28
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
More to learn about reducing the churn: Examining the pandemic’s continuous enrollment Medicare policy
2023-11-28
Boston, MA – A new study led by researchers at the Harvard Pilgrim Health Care Institute has found that a federal policy implemented during the COVID-19 pandemic requiring continuous enrollment in Medicaid led to a significant reduction in the rates of becoming uninsured for adult Medicaid enrollees.
The study, “Continuous Medicaid coverage during the COVID-19 public health emergency reduced churning, but did not eliminate it,” was published in the October 21 edition of Health Affairs Scholar.
Many people who have Medicaid coverage frequently gain and lose it, sometimes over short periods of time. This phenomenon ...
No significant link between industry 4.0 and energy consumption or energy intensity
2023-11-28
To what extent does the digitalisation of industrial and manufacturing processes (Industry 4.0) improve energy efficiency and thus reduce energy intensity? A team from the Research Institute for Sustainability (RIFS) analysed developments across ten industrial manufacturing sectors in China between 2006 and 2019. Their findings show that contrary to the claims of many policymakers and industry associations, digitalisation may not automatically lead to anticipated energy savings in manufacturing and industry in China.
China accounts for 30% of global manufacturing value added and the largest share of global manufacturing ...
Weill Cornell Medicine to open medical research center at 1334 York Avenue
2023-11-28
Weill Cornell Medicine is dramatically expanding its campus and research footprint in New York City by securing five floors of 1334 York Ave., the current home of Sotheby's auction house, the institution announced today.
Located one block from Weill Cornell Medicine’s main campus on Manhattan’s Upper East Side, the site will add approximately 200,000 square feet of dedicated research space—an average of 40,000 square feet per floor—making it the institution’s largest expansion since the Belfer Research Building opened in 2014. Laboratories in the new medical ...
What if Alexa or Siri sounded more like you? Study says you’ll like it better
2023-11-28
UNIVERSITY PARK, Pa. — One voice does not fit all when it comes to virtual assistants like Siri and Alexa, according to a team led by Penn State researchers that examined how customization and perceived similarity between user and voice assistant (VA) personalities affect user experience. They found a strong preference for extroverted VAs — those that speak louder, faster and in a lower pitch. They also found that increasing personality similarity by automatically matching user and VA voice profiles encouraged users to resist persuasive information, such as misinformation about COVID-19 vaccines. In the study, 38% of unvaccinated individuals changed their minds about vaccination ...
A gamma-ray pulsar milestone inspires innovative astrophysics and applications
2023-11-28
WASHINGTON – The U.S. Naval Research Laboratory (NRL), in conjunction with the international Fermi Large Area Telescope Collaboration, announce the discovery of nearly 300 gamma ray pulsars in the publication of their Third Catalog of Gamma Ray Pulsars. This milestone comes 15 years since the launch of Fermi in 2008, when there were fewer than ten known gamma-ray pulsars.
“Work on this important catalog has been going on in our group for years,” said Paul Ray, Ph.D., head of the High Energy Astrophysics and Applications Section ...
Recent scientific studies offer insight into heart and stroke health
2023-11-28
DALLAS, Nov. 28, 2023 — More than 4,000 abstracts were presented during the American Heart Association’s Scientific Sessions 2023 and Resuscitation Science Symposium 2023, held earlier this month in Philadelphia. Here are some of the important scientific findings that could impact your heart and stroke health.
Next wave of AI prediction models aims to predict risk of heart attack and stroke, as well as heart valve disease
Artificial intelligence (AI) and deep learning models may help to predict the risk of cardiovascular disease events and detect heart ...
Montefiore Einstein Comprehensive Cancer Center awarded FDA grant for clinical trial on experimental AML/MDS treatment
2023-11-28
November 28, 2023—(BRONX, NY)—Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)—two related blood diseases that disproportionally strike older adults—are notoriously difficult to treat and associated with high relapse rates. Although new therapies have improved survival, treatment options remain limited, and the prognosis for the 50% of people who experience disease relapse remains poor.
Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive ...
LSU Health Shreveport chooses Digital Science to support research discovery and integrity
2023-11-28
Digital Science, a technology company serving stakeholders across the research ecosystem, is pleased to announce that Louisiana State University Health Shreveport (LSUHS) has chosen Dimensions Analytics and Dimensions Research Security from Digital Science’s flagship products to advance its world-class research programs.
LSUHS is one of the first customers to subscribe to the new Dimensions Research Security app. The institution – one of the leading health science research programs in the U.S. – has signed a three-year deal to utilize the two products ...
Understanding the impact of transferring patients with dementia between hospitals
2023-11-28
INDIANAPOLIS – It is common for individuals seeking medical care for symptoms of concern to go to the nearest hospital. Physicians there may determine the facility cannot provide the care they believe the patient needs and recommend transfer to another hospital offering a higher level of care or specialized services.
In a recent study, researchers from Regenstrief Institute and Indiana University School of Medicine reviewed electronic health records to compare older adults with dementia transferred to another hospital with older adults who did not have dementia. The researchers found significant differences in treatment following transfer.
Patients with dementia more ...
The secret life of an electromagnon
2023-11-28
Scientists have revealed how lattice vibrations and spins talk to each other in a hybrid excitation known as an electromagnon. To achieve this, they used a unique combination of experiments at the X-ray free electron laser SwissFEL. Understanding this fundamental process at the atomic level opens the door to ultrafast control of magnetism with light.
Within the atomic lattice of a solid, particles and their various properties cooperate in wave like motions known as collective excitations. When atoms in a lattice jiggle together, the collective excitation is known as a phonon. Similarly, when the atomic spins - the magnetisation of the atoms -move together, it’s ...